Lonatra 2,3 %+1,75 mmol/l peritonealdialysevæske Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

lonatra 2,3 %+1,75 mmol/l peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske - 2,3 %+1,75 mmol/l

Lonatra 4,25 %+1,25 mmol/l peritonealdialysevæske Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

lonatra 4,25 %+1,25 mmol/l peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natrium(s)-lactat opløsning, natriumchlorid - peritonealdialysevæske - 4,25 %+1,25 mmol/l

Lonatra 4,25 %+1,75 mmol/l peritonealdialysevæske Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

lonatra 4,25 %+1,75 mmol/l peritonealdialysevæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, magnesiumchloridhexahydrat, natriumchlorid, natriumlactat opløsning - peritonealdialysevæske - 4,25 %+1,75 mmol/l

Multibic 3 mmol/l kalium hæmodialyse-/hæmofiltreringsvæske Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

multibic 3 mmol/l kalium hæmodialyse-/hæmofiltreringsvæske

fresenius medical care deutschland gmbh - calciumchloriddihydrat, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumchlorid, natriumhydrogencarbonat - hæmodialyse-/hæmofiltreringsvæske - 3 mmol/l

Infusolec infusionsvæske, opløsning Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

infusolec infusionsvæske, opløsning

dechra regulatory b.v. - calciumchloriddihydrat, kaliumchlorid, natriumchlorid, natriumlactat - infusionsvæske, opløsning - hest, hund, kat, kvæg

Gelaspan 40 mg/ml infusionsvæske, opløsning Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

gelaspan 40 mg/ml infusionsvæske, opløsning

orifarm a/s - calciumchloriddihydrat, gelatinepolysuccinat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 40 mg/ml

Benelyte 6,429+0,298+0,147+0,203+4,082+11,0 mg/ml infusionsvæske, opløsning Dánsko - dánčina - Lægemiddelstyrelsen (Danish Medicines Agency)

benelyte 6,429+0,298+0,147+0,203+4,082+11,0 mg/ml infusionsvæske, opløsning

fresenius kabi ab - calciumchloriddihydrat, glucosemonohydrat, kaliumchlorid, magnesiumchloridhexahydrat, natriumacetattrihydrat, natriumchlorid - infusionsvæske, opløsning - 6,429+0,298+0,147+0,203+4,082+11,0 mg/ml

Degarelix Accord Európska únia - dánčina - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatiske neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Renagel Európska únia - dánčina - EMA (European Medicines Agency)

renagel

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - alle andre terapeutiske produkter - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Crysvita Európska únia - dánčina - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.